Tumor Hypoglycemia Linked to IGF-II
1999; Humana Press; Linguagem: Inglês
10.1007/978-1-59259-712-3_28
AutoresChristian A. Koch, Kristina I. Rother, Jesse Roth,
Tópico(s)Pancreatic and Hepatic Oncology Research
ResumoHypoglycemia is a common medical emergency, most often due to untoward effects of insulin administered to patients with diabetes mellitus. It is also a manifestation of many other medical conditions including tumors. The hypoglycemia associated with tumors occurs within a subset of patients who have "spontaneous" or fasting hypoglycemia, i.e., the fall in blood glucose to subnormal levels occurs apparently unprovoked several hours after the patient has last eaten. Historically, the first and still the most common tumors with hypoglycemia are insulinomas, the insulin-secreting tumors of the endocrine pancreas. All other tumors associated with hypoglycemia are referred to under the broad rubric of non-islet-cell tumors with hypoglycemia (NICTH). The most important group of patients with NICTH are those who harbor tumors that secrete an incompletely processed form of insulin-like growth factor-II (IGF-II), known as big IGF-II. The tumor types included in this group are extremely numerous and are the major focus of our discussion.
Referência(s)